| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(5 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(11 years from now) | |
Orbactiv is owned by Melinta Therap.
Orbactiv contains Oritavancin Diphosphate.
Orbactiv has a total of 3 drug patents out of which 0 drug patents have expired.
Orbactiv was authorised for market use on 06 August, 2014.
Orbactiv is available in powder;intravenous dosage forms.
Orbactiv can be used as treatment of bacterial skin and skin structure infections, treatment of bacterial skin and skin structure infections using a single dose.
Drug patent challenges can be filed against Orbactiv from 2023-08-07.
The generics of Orbactiv are possible to be released after 16 July, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 6, 2019 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 6, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 2023-08-07
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections
Dosage: POWDER;INTRAVENOUS
ORBACTIV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic